Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

COPD: Pathogenesis and Clinical Features

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Airway wall thickness and PRISm are associated with cognitive impairment in individuals with cigarette smoking exposure.

Respiratory research·2026

Same author

BioNeuralNet: a graph neural network based Multi-Omics network data analysis tool.

Bioinformatics (Oxford, England)·2026

Same author

Electronic cigarette aerosols disrupt airway barrier function via MMP-dependent E-cadherin cleavage: findings from cell culture and murine models.

Archives of toxicology·2026

Same author

High agreement of coronary artery calcification scores between full-dose (6.5 mSv) and reduced-dose (1.5 mSv) chest computed tomography: A retrospective analysis of COPDGene.

Journal of cardiovascular computed tomography·2026

Same author

Discriminative Performance and Clinical utility of COPD Exacerbation Categories for Predicting Future Exacerbations.

American journal of respiratory and critical care medicine·2026

Same author

Vascular-related proteomic signatures in COPD with suspected pulmonary hypertension as predictors of FEV₁ impairment.

Respiratory research·2026

Search research articles

Related Experiment Video

Updated: Nov 21, 2025

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

Protein Biomarkers for COPD Outcomes.

Karina A Serban¹, Katherine A Pratte², Russell P Bowler¹

¹National Jewish Health, Denver; University of Colorado, Anschutz Medical Campus, Aurora, CO.

|January 12, 2021

Summary

Identifying protein biomarkers for chronic obstructive pulmonary disease (COPD) is crucial for risk assessment. This review highlights novel biomarkers and emphasizes the need for panels to fully capture COPD risk.

Keywords:

COPD biomarker network multiplex platforms protein biomarker

More Related Videos

Automated Measurement of Pulmonary Emphysema and Small Airway Remodeling in Cigarette Smoke-exposed Mice

Automated Measurement of Pulmonary Emphysema and Small Airway Remodeling in Cigarette Smoke-exposed Mice

Published on: January 16, 2015

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Related Experiment Videos

Last Updated: Nov 21, 2025

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

Automated Measurement of Pulmonary Emphysema and Small Airway Remodeling in Cigarette Smoke-exposed Mice

Automated Measurement of Pulmonary Emphysema and Small Airway Remodeling in Cigarette Smoke-exposed Mice

Published on: January 16, 2015

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Area of Science:

Pulmonary Medicine
Biomarker Discovery
Omics Technology

Background:

Chronic obstructive pulmonary disease (COPD) is a heterogeneous syndrome linked to environmental exposures and systemic injury.
Not all exposed individuals develop COPD, necessitating the search for risk biomarkers.
Existing research focuses on outcomes like FEV1, emphysema, and exacerbations.

Purpose of the Study:

To review and summarize evidence for protein biomarkers associated with clinically relevant COPD outcomes.
To discuss the advantages, weaknesses, and clinical translation challenges of these biomarkers.
To explore the potential of novel biomarkers and biomarker panels for COPD risk stratification.

Main Methods:

Literature review focusing on protein biomarkers for COPD.
Analysis of omics data and molecular phenotyping of COPD cohorts.
Evaluation of biomarkers linked to FEV1, FEV1 decline, emphysema, and exacerbations.

Main Results:

Alpha-1 antitrypsin is a prototypic but insufficient biomarker, accounting for only 1-5% of COPD cases.
Novel biomarkers such as fibrinogen, surfactant protein D, and club cell secretory protein show promise.
Individual biomarkers explain only a fraction of COPD risk.

Conclusions:

Multiple biomarker panels are essential for comprehensive risk assessment in COPD.
Further research and regulatory steps are needed to translate bench findings into clinical practice.
Biomarker discovery is key to understanding and managing COPD heterogeneity and systemic effects.